Clinicopathology Figures of Breast Cancer Women with Brain Metastasis and Invasive Ductal Carcinoma

Mehrnoush Aeinfar¹, Safa Najafi², Mehrdad Payandeh¹, Masoud Sadeghi^{3, 4,} and Edris Sadeghi^{3, 4}

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Breast Diseases Department, Breast Cancer Research Centre, ACECR, Iran

³Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrnoush Aeinfar, Safa Najafi, Mehrdad Payandeh, Masoud Sadeghi and Edris Sadeghi. Clinicopathology Figures of Breast Cancer Women with Brain Metastasis and Invasive Ductal Carcinoma. American Journal of Cancer Prevention. 2015; 3(3):68-71. doi: 10.12691/ajcp-3-3-6

Abstract

Background: Breast cancer (BC) metastasis to the central nervous system (CNS) or brain metastases include the clinically distinct situations of multiple brain metastasis (78%), solitary brain metastasis (14%), and leptomeningeal metastasis (8%). The aim of this study is to describe clinicopathologic features of patients with BC brain metastasis and to compare estrogen receptor (ER), progesterone receptor (PR), and Her2 expression in them. Materials and Methods: there were 16 patients with brain metastasis and we entered them to our study. Age, sex, kind of pathology, tumor markers, type of treatment, histological grade, size of tumor, laterality and other metastasizes were checked for the patients. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2 positivity was defined as either HER2 gene amplification by fluorescent in situ hybridization or scored as 3+ by IHC. Results: The mean age at diagnosis for the patients was 42.2 years (±14.4) and range of 27 to 73 years that 100% were female. ER, PR, Her-2 and p53 positive for the patients were 43.7%, 56.3%, 43.7% and 37.5%, respectively. Three patients (18.7%) had grade I, nine patients (56.3%) had grade II and four patients (25%) had grade III. The mean OS was 24.7 months with survival rate of 50%. Lymph node metastasis for 13 patients (81.2%) was positive. Conclusions: The mean age for patients with brain metastatic BC at diagnosis is more between 45 to 52 years and also brain metastasis in BC occurs more in HER-2-overexpressing and TNBC. Size of tumor in BC patients >5 cm is a prognostic factor for brain metastasis.

Keywords:
brain metastasis breast cancer ER Ki67

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Payandeh M, Sadeghi M, Fekri A, Sadeghi E. P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran, Journal of Solid Tumors, 4 (3), 4-9, 2014.
[2]	Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer, J Clin Oncol, 22, 3608-3617, 2004.
[3]	Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system, Am J Pathol, 167, 913-920, 2005.
[4]	Wadasadawala T, Gupta S, Bagul V, Patil N. Brain metastases from breast cancer: management approach, J Cancer Res Ther, 3 (3), 157-65, 2007.
[5]	Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways, Cancer Treat Rev, 38, 698-707, 2012.
[6]	Anderson A, Choy C, Neman J, Duenas MJ, Jandial R, Somlo G. Metastatic Breast Cancer to the Brain: A Clinical Primer for Translational Investigation. Metastatic Cancer: Clinical and Biological Perspectives edited by Rahul Jandial. ©2013 Landes Bioscience.
[7]	Brady-West DC, McGrowder DA. Triple Negative Breast Cancer: Therapeutic and Prognostic Implications, Asian Pac J Cancer Prev, 12 (8), 2139-43, 2011.
[8]	Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature, Iran J Cancer Prev, 8 (2), 125-8, 2015.
[9]	Payandeh M, Sadeghi M, Sadeghi E, koohian AK. Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran, American Journal of Cancer Prevention, 2 (2), 37-41, 2014.
[10]	Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases, American Journal of Cancer Prevention, 3 (1), 4-7, 2015.
[11]	Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy, Ann Oncol, 16, 1772-7, 2005.
[12]	Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer, Br J Cancer, 91, 639-43, 2004.
[13]	Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma, Cancer, 97, 2972-7, 2003.
[14]	de Vries EG. 11th International Conference on Primary Breast Cancer, St.Gallen, Switzerland, Molecular imaging of breast cancer, 2009.
[15]	Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system, Am J Pathol, 167 (4), 913-20, 2005.
[16]	Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases, Proc Natl Acad Sci U S A, 109, E3119-27, 2012.
[17]	Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, et al. Distant metastasis in triple-negative breast cancer, Neoplasma, 60, 290-4, 2013.
[18]	Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat.2008.111 (3):523-30.
[19]	Ogura M, Mitsumori M, Okumura S, Yamauchi C, Kawamura S, Oya N, et al. Radiation therapy for brain metastases from breast cancer, Breast Cancer, 10 (4), 349-55, 2003.
[20]	Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy, Cancer Med, 2015.
[21]	Pestalozzi BC. Brain metastases and subtypes of breast cancer, Ann Oncol, 20 (5), 803-5, 2009.
[22]	Zhang T, Li Q, Xu B, Zhang P, Yuan P, Ma F, et al. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes], Zhonghua Zhong Liu Za Zhi, 36 (9), 697-702, 2014.
[23]	Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, et al. Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis, Oncologist, 2015.
[24]	Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment, Cancer, 101, 1760-6, 2004.
[25]	Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival, Ann Oncol, 14, 1072-7, 2003.
[26]	Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, et al. Brain metastases from breast cancer: Identification of a high-risk group, Clin Oncol (R Coll Radiol), 16, 345-9, 2004.
[27]	Margolese RG, Hortobagyi GN, Buchholz TA. Management of Metastatic Breast Cancer. Holland-Frei Cancer Medicine. 6th edition.
[28]	Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, et al. Determinants and prognoses of locoregional and distant progression in breast cancer, Int J Radiat Oncol Biol Phys, 55, 1186-95, 2003.
[29]	Jaboin JJ, Ferraro DJ, DeWees TA, Rich KM, Chicoine MR, Dowling JL, e al. Survival following gamma knife radiosurgery for brain metastasis from breast cancer, Radiat Oncol, 8, 131, 2013.